Treatments for fragile X syndrome: a closer look at the data
1Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA 94305-5795, USA. hallss@stanford.edu
Abstract:
Research into the determinants and developmental course of fragile X syndrome (FXS) has made remarkable progress over the last 25 years. However, treatments to ameliorate the symptoms of FXS have been less forthcoming. While there is optimism in the field that the pace of intervention research is quickening, there has been a bias toward psychopharmacological approaches to treatment. A closer look at the data from those investigations reveals a paucity of evidence that medications can improve intellectual and adaptive functioning in FXS, or decrease associated behavioral and/or emotional issues. Work in other related disorders (e.g., autism) has shown that dramatic improvements in intellectual and adaptive functioning, as well as behavioral and emotional problems, can occur if intensive behavioral treatment is begun early in the child's life. It is hoped that future research efforts will evaluate these intensive early intervention strategies in children with FXS, perhaps in combination with pharmacological approaches.
Insights
Fragile X syndrome (FXS) research shows limited medication benefits for cognitive and behavioral symptoms. Early intensive behavioral interventions, successful in related disorders, are recommended for future FXS research.
Area of Science:
- Neuroscience
- Developmental Psychology
- Genetics
Background:
- Fragile X syndrome (FXS) research has advanced in understanding its causes and development.
- Treatment development for FXS symptoms has lagged behind research progress.
- Current intervention research shows a bias towards psychopharmacological treatments.
Purpose of the Study:
- To evaluate the effectiveness of current treatment approaches for fragile X syndrome.
- To explore alternative intervention strategies for improving outcomes in FXS.
- To address the need for evidence-based treatments that enhance cognitive and adaptive functioning.
Main Methods:
- Review of existing research on psychopharmacological interventions for FXS.
- Analysis of data from studies on related neurodevelopmental disorders, such as autism.
- Identification of potential therapeutic targets and intervention modalities.
Main Results:
- Limited evidence suggests medications do not significantly improve intellectual or adaptive functioning in FXS.
- Psychopharmacological approaches show minimal impact on associated behavioral and emotional issues.
- Intensive behavioral interventions in related disorders have demonstrated significant improvements.
Conclusions:
- Future research should prioritize evaluating intensive early behavioral intervention strategies for children with FXS.
- Combining behavioral interventions with pharmacological approaches may offer a more comprehensive treatment plan.
- There is a critical need for evidence-based, non-pharmacological treatments to improve quality of life for individuals with FXS.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
10:58TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism
Published on: December 28, 2010
Related Concept Videos
01:43Sex-linked Disorders
01:22Alzheimer's Disease: Treatment
01:43Sex Linked Disorders
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...